Prudential Financial Inc. boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 25.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 559,765 shares of the company's stock after acquiring an additional 112,352 shares during the period. Prudential Financial Inc.'s holdings in Teva Pharmaceutical Industries were worth $12,337,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Stifel Financial Corp increased its holdings in shares of Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after purchasing an additional 23,283 shares during the period. Robeco Institutional Asset Management B.V. increased its stake in Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after buying an additional 33,277 shares during the period. Sio Capital Management LLC acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at $24,314,000. Pinnbrook Capital Management LP purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth $4,966,000. Finally, Asset Management One Co. Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 14.6% in the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after acquiring an additional 58,413 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research firms recently issued reports on TEVA. StockNews.com cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Thursday, March 27th. Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. UBS Group reduced their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Bank of America cut their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Finally, Piper Sandler raised their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $23.43.
Check Out Our Latest Stock Analysis on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Price Performance
NYSE TEVA traded down $0.05 during mid-day trading on Wednesday, hitting $15.25. The stock had a trading volume of 1,727,462 shares, compared to its average volume of 12,164,169. The company has a 50 day simple moving average of $16.95 and a 200 day simple moving average of $18.08. The company has a market cap of $17.29 billion, a price-to-earnings ratio of -10.51, a P/E/G ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.
About Teva Pharmaceutical Industries
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
